WO2025202874 - GENETICALLY MODIFIED CELLS EXPRESSING GLP-1 RECEPTOR AGONIST
National phase entry is expected:
Publication Number
WO/2025/202874
Publication Date
02.10.2025
International Application No.
PCT/IB2025/053108
International Filing Date
24.03.2025
Title **
[English]
GENETICALLY MODIFIED CELLS EXPRESSING GLP-1 RECEPTOR AGONIST
[French]
CELLULES GÉNÉTIQUEMENT MODIFIÉES EXPRIMANT UN AGONISTE DU RÉCEPTEUR DE GLP-1
Applicants **
CRISPR THERAPEUTICS AG
Inventors
LIAO, Meichen
Priority Data
63/569,424
25.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4756 | |
| EPO | Filing, Examination, Granting | 72157 | |
| Japan | Filing, Examination, Granting | 4298 | |
| South Korea | Filing, Examination, Granting | 6336 | |
| USA | Filing, Examination, Granting | 19190 |
Total:
106,737
Contact Us
Abstract[English]
Disclosed herein include methods, compositions, and kits suitable for use in treating diseases or disorders related to insulin signaling. In some embodiments, the method comprises editing stem cells to express a GLP-1 receptor agonist. Also provided are compositions comprising the edited cells expressing a GLP-1 receptor agonist to treat, e.g., diabetes.[French]
La divulgation concerne des procédés, des compositions et des kits appropriés pour être utilisés dans le traitement de maladies ou de troubles liés à la signalisation de l'insuline. Dans certains modes de réalisation, le procédé comprend la modification de cellules souches pour exprimer un agoniste du récepteur de GLP-1. La divulgation concerne également des compositions comprenant les cellules modifiées exprimant un agoniste du récepteur de GLP-1 pour traiter, par exemple, le diabète.